Evidence map›Paper›PMID 39802916›Full record

ArticleJournal of molecular and cellular cardiology plus2024

The cardiac blood transcriptome predicts de novo onset of atrial fibrillation in heart failure.

Guillaume Lamirault, Imen Fellah-Hebia, Catherine Chevalier, Isabelle Guisle, Béatrice Guyomarc'h, Aude Solnon, Jean-Baptiste Gourraud, Laurent Desprets, Selim Abbey, Christophe Leclercq and 9 more

Abstract read
In one paragraph

Article in Journal of molecular and cellular cardiology plus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Guillaume LamiraultNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Imen Fellah-HebiaNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Catherine ChevalierNantes Université, CHU Nantes, CNRS, INSERM, BioCore, US16, SFR Bonamy, F-44000 Nantes, France.
Isabelle GuisleNantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Béatrice Guyomarc'hNantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Aude SolnonNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Jean-Baptiste GourraudNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Laurent DespretsNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Selim AbbeyNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Christophe LeclercqDépartement de Cardiologie, CHU Pontchaillou, Rennes, France.
Paul BruService de Cardiologie, CH La Rochelle, La Rochelle, France.
Antoine MilhemService de Cardiologie, CH La Rochelle, La Rochelle, France.
Olivier BillonDepartment of Cardiovascular Medicine, Vendée Hospital, Service de Cardiologie, La Roche sur Yon, France.
Frederic AnselmeCardiology Department, Rouen University Hospital, Rouen, France.
Arnaud SavouréCardiology Department, Rouen University Hospital, Rouen, France.
Jean-Noël TrochuNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Rémi HoulgatteINSERM, U1256, NGERE - Nutrition, Genetics, and Environmental Risk Exposure, Faculty of Medicine of Nancy, University of Lorraine, Vandoeuvre-lès-, Nancy, France.
Gilles LandeNantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
Marja SteenmanNantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) increases the risk of developing atrial fibrillation (AF), leading to increased morbidity and mortality. Therefore, better prediction of this risk may improve treatment strategies. Although several predictors based on clinical data have been developed, the establishment of a transcriptome-based predictor of AF incidence in HF has proven to be more problematic. We hypothesized that the transcriptome profile of coronary sinus blood samples of HF patients is associated with AF incidence. We therefore enrolled 192 HF patients who were selected for biventricular cardioverter defibrillator implantation. Both coronary sinus and peripheral blood samples were obtained during the procedure. Patients were followed-up during two years and AF occurrence was based on interrogation of the defibrillator. A total of 96 patients stayed in sinus rhythm (SR) during follow-up, 13 patients developed AF within 1 year and 10 patients developed AF during the second year of follow up. Gene expression profiling of coronary sinus samples led to the identification of 321 AF predictor genes based on their differential expression between patients developing AF within 1 year of blood sampling and patients remaining in SR. The expression levels of these genes were combined to obtain a molecular atrial fibrillation prediction score for each patient which was significantly different between both patient groups (Mann-Whitney,

Indexed as

Atrial fibrillationCoronary sinus bloodHeart failurePrognostic biomarkersTranscriptomic profiling

Identifiers

PMID39802916
PMCPMC11708251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.